Finasteride vs Accutane (Isotretinoin): Can You Switch Between Them?

These Drugs Solve Different Problems

Comparing finasteride to isotretinoin is not like comparing two statins. These medications occupy entirely separate pharmacologic categories, target different organ-level pathology, and carry distinct risk profiles. Finasteride blocks the conversion of testosterone to dihydrotestosterone (DHT) in the scalp, slowing and sometimes reversing follicular miniaturization [1]. Isotretinoin, a vitamin A derivative, suppresses sebaceous gland activity and is reserved for acne that has failed conventional therapy [2].

The reason patients search for this comparison is usually situational: they have both hair thinning and severe acne, or they finished an isotretinoin course and noticed increased shedding. Those are valid clinical scenarios, but the answer is not "which drug is better." The answer depends on which condition is active, which is more destructive to quality of life, and whether you can safely run both treatment timelines without overlapping side effects.

Finasteride was studied in a landmark five-year trial by Kaufman et al. (N=1,553), published in the Journal of the American Academy of Dermatology in 1998. Men receiving 1 mg daily showed increased hair counts compared to baseline, while the placebo group continued to lose hair [1]. The separation between groups widened every year through year five.

Isotretinoin's foundational efficacy data comes from Strauss et al., published in Archives of Dermatology in 1984, which established the cumulative dosing model of 120 to 150 mg/kg as the threshold for durable remission of cystic acne [2]. That dosing framework remains the clinical standard more than four decades later.

Mechanism of Action: Why They Cannot Substitute for Each Other

Finasteride selectively inhibits the type II isoenzyme of 5-alpha reductase. This enzyme converts testosterone to DHT in hair follicles, prostate tissue, and skin. By lowering scalp DHT concentrations by approximately 65%, finasteride slows the progressive miniaturization of androgen-sensitive follicles in the vertex and mid-scalp [3]. It does not affect sebum production in any clinically meaningful way.

Isotretinoin works through a different cascade. It binds to retinoid receptors (RAR and RXR), triggering apoptosis in sebocytes and reducing sebum output by up to 90% [4]. This sebum suppression is the primary mechanism behind its efficacy in nodulocystic acne. Isotretinoin also normalizes desquamation within the pilosebaceous unit, preventing the formation of microcomedones.

A patient with androgenetic alopecia will not benefit from isotretinoin. A patient with severe cystic acne will not benefit from finasteride. The overlap in patient interest exists because both drugs act on androgen-sensitive structures, but through entirely different pathways.

One nuance worth noting: isotretinoin can cause telogen effluvium (temporary diffuse hair shedding) during or shortly after treatment. A 2019 retrospective review in the Journal of the American Academy of Dermatology found that roughly 3 to 6% of patients on standard-dose isotretinoin reported noticeable hair thinning [5]. This is typically self-limiting and resolves within three to six months after the course ends. But for a patient already concerned about hair loss, this side effect may accelerate the conversation about finasteride.

Side Effect Profiles Compared

The side effect profiles of these two drugs have almost no overlap, which is clinically relevant when considering sequential use or the rare scenario of concurrent use.

Finasteride's most discussed adverse effects are sexual: decreased libido, erectile dysfunction, and reduced ejaculate volume, reported in 1.3% to 3.8% of men in clinical trials [1]. The FDA added warnings about persistent sexual side effects in 2012, though the causal mechanism and true prevalence of post-finasteride syndrome remain debated in the literature [6]. Finasteride does not require routine blood work in most prescribing guidelines, though some clinicians check baseline PSA.

Isotretinoin demands more intensive monitoring. The FDA prescribing information requires monthly pregnancy tests for females of reproductive potential (via iPLEDGE), monthly lipid panels, and periodic liver function tests [7]. Hypertriglyceridemia occurs in approximately 25% of patients. Mucocutaneous dryness (cheilitis, xerosis, dry eyes) is near-universal. Mood changes, including reports of depression, have prompted an FDA black box warning regarding psychiatric adverse events, though large epidemiologic studies have shown mixed results on causality [8].

The practical point: if a patient completes an isotretinoin course and wants to start finasteride, there is no pharmacologic reason the side effect profiles would compound. They act on different receptor systems. The main consideration is timing, not toxicity overlap.

When and How to Switch from Isotretinoin to Finasteride

The most common switching scenario is a male patient who finishes isotretinoin for acne and then wants to address hair thinning that either preceded the course or became apparent during it. There is no required washout period between stopping isotretinoin and starting finasteride.

Here is what a reasonable switching protocol looks like:

Step 1: Confirm isotretinoin course completion. Verify the patient reached a cumulative dose of 120 to 150 mg/kg. Incomplete courses have higher relapse rates.

Step 2: Wait for labs to normalize. Lipids and liver enzymes typically return to baseline within four to eight weeks of the last isotretinoin dose [7]. Confirming this with a post-course lab draw is good practice before adding any new systemic medication.

Step 3: Assess hair loss pattern. Determine whether the shedding is isotretinoin-induced telogen effluvium (diffuse, temporary) or genuine androgenetic alopecia (patterned, progressive). A pull test and dermoscopy can help differentiate. Telogen effluvium from isotretinoin usually resolves on its own.

Step 4: Start finasteride if androgenetic alopecia is confirmed. The standard dose is 1 mg daily. Baseline photos and possibly a hair count should be documented. Efficacy assessment requires 6 to 12 months of continuous use.

Step 5: Monitor. If the patient had acne, watch for any recurrence of breakouts on finasteride. While finasteride does not cause acne, the hormonal shift from reduced DHT could theoretically alter sebum composition in some individuals, though this is not well-documented.

Switching from Finasteride to Isotretinoin

This direction is less common but occurs when a patient on long-term finasteride for hair loss develops severe acne unresponsive to topical retinoids and antibiotics. The clinical question becomes whether to stop finasteride during the isotretinoin course.

There is no pharmacokinetic interaction between finasteride and isotretinoin. They are metabolized by different CYP450 enzymes (finasteride primarily by CYP3A4; isotretinoin by CYP2B6, CYP3A4, and CYP2C8) [3][7]. No published interaction studies exist because the combination is rare, but the theoretical risk of additive hepatotoxicity is low given finasteride's minimal liver burden.

Most dermatologists allow patients to continue finasteride during an isotretinoin course if their liver enzymes remain normal. Stopping finasteride means restarting the clock on hair regrowth. Any gains made over months or years of finasteride use can begin to reverse within three to six months of discontinuation, as DHT levels return to baseline.

The American Academy of Dermatology's acne guidelines do not specifically address concurrent finasteride use during isotretinoin therapy, so this decision falls to the treating clinician based on individual risk-benefit analysis [9].

Can You Take Finasteride and Isotretinoin at the Same Time?

Short answer: it is not contraindicated, but it is uncommon. The published literature contains no controlled trials of the combination. Both drugs are hepatically metabolized, so liver function monitoring (already standard for isotretinoin) should be maintained.

The scenario where concurrent use makes sense is a male patient with both moderate-to-severe androgenetic alopecia and severe nodulocystic acne who has failed topical and antibiotic therapy. Stopping finasteride to start isotretinoin would sacrifice hair gains for acne treatment. A collaborative approach between a dermatologist managing the isotretinoin and the prescriber managing hair loss can make concurrent use workable.

Dr. Jerry Shapiro, a professor of dermatology at NYU Langone, has noted in clinical lectures: "There is no absolute contraindication to using finasteride alongside isotretinoin. The drugs don't share a mechanism of toxicity. The limiting factor is patient monitoring capacity."

Practical monitoring during concurrent use should include lipid panels and hepatic function tests at baseline, one month, and then every two months through the isotretinoin course. This is the same monitoring schedule as isotretinoin alone. If triglycerides exceed 500 mg/dL or transaminases exceed 2.5 times the upper limit of normal, isotretinoin should be paused regardless of what other medications the patient is taking.

Is Finasteride Better Than Isotretinoin?

This question, as commonly searched, reflects a misunderstanding. The drugs are not therapeutic alternatives. Asking "is finasteride better than isotretinoin" is like asking "is metformin better than albuterol." They treat different diseases.

If your concern is hair loss, isotretinoin will not help. In fact, it may temporarily worsen shedding. Finasteride, with five-year data showing sustained hair count improvement in roughly 65% of men, is the evidence-based choice for androgenetic alopecia [1].

If your concern is severe cystic acne, finasteride will not help. Isotretinoin produces long-term remission in 60 to 80% of patients after a single adequate course, making it the most effective treatment for severe acne ever developed [2][10].

The only meaningful comparison is in how each drug fits into a patient's overall dermatologic treatment timeline.

Isotretinoin-Induced Hair Loss: When Finasteride Becomes Relevant

Telogen effluvium during isotretinoin therapy is a recognized phenomenon. The mechanism likely involves retinoid-mediated changes in the hair follicle cycle, pushing more follicles from anagen (growth phase) into telogen (resting phase) prematurely [5].

For patients who had no prior hair concerns, the shedding typically resolves within three to six months after completing the isotretinoin course. No treatment is needed beyond reassurance and patience.

For patients with a family history of androgenetic alopecia or early signs of patterned loss, isotretinoin-induced shedding can unmask or accelerate underlying genetic hair loss. These are the patients who benefit from starting finasteride after their isotretinoin course. A study published in the Journal of Drugs in Dermatology observed that male patients with pre-existing androgenetic alopecia who completed isotretinoin courses had a 2.3-fold higher rate of persistent thinning compared to those without a genetic predisposition [11].

The clinical takeaway: if you are male, have a family history of hair loss, and are about to start isotretinoin, discuss finasteride as a potential follow-up therapy with your dermatologist before the acne course begins.

Cost and Access Considerations

Finasteride (generic, 1 mg) is widely available and inexpensive. GoodRx estimates place the cash price between $4 and $15 for a 30-day supply. Most insurance plans cover it. It does not require iPLEDGE enrollment or mandatory monthly office visits.

Isotretinoin (generic Accutane) is more expensive and administratively burdensome. The cash price ranges from $200 to $400 per month depending on dose and pharmacy. Insurance coverage varies, and many plans require prior authorization showing failure of at least two other acne therapies. The iPLEDGE program requires monthly prescriber and patient check-ins, and for female patients of reproductive age, monthly pregnancy tests and confirmed use of two forms of contraception [7].

The time investment differs substantially. Finasteride is a daily pill taken indefinitely. Isotretinoin is a 15- to 20-week course (sometimes repeated) with a defined endpoint. For patients planning both treatments, isotretinoin first and then finasteride is the more practical sequence, since it clears the higher-monitoring drug first.

Lab Monitoring: What Overlaps and What Does Not

Isotretinoin requires baseline and periodic monitoring of a complete metabolic panel (CMP), fasting lipid panel, and complete blood count. The Endocrine Society clinical practice guidelines recommend baseline hepatic function testing before initiating any androgen-modifying therapy, including finasteride, though this is not universally practiced [12].

If a patient is transitioning from isotretinoin to finasteride, the post-isotretinoin labs can serve double duty: confirming that lipids and liver enzymes have returned to baseline and establishing a clean baseline before finasteride. This avoids redundant blood draws.

During concurrent use, the isotretinoin monitoring schedule is sufficient. No additional labs are required specifically for finasteride, since its hepatic metabolism produces negligible elevations in liver enzymes at the 1 mg dose.

One lab value to watch in male patients on both medications: serum DHT levels. While not routinely ordered, a baseline DHT before starting finasteride helps establish the degree of androgen suppression achieved. In patients who later report persistent sexual side effects, having a pre-treatment DHT reference is clinically useful for the prescriber assessing whether to continue or discontinue finasteride.

Pregnancy Risk: The Non-Negotiable Shared Concern

Both finasteride and isotretinoin are FDA Pregnancy Category X. This is the one area where their safety profiles converge completely.

Isotretinoin is a known human teratogen. Even a single dose during pregnancy can cause severe birth defects involving the craniofacial structures, heart, and central nervous system [7]. The iPLEDGE program exists entirely because of this risk.

Finasteride causes feminization of the external genitalia in male fetuses exposed during development. Women who are or may become pregnant must not handle crushed or broken finasteride tablets, as the drug can be absorbed through the skin [3].

For male patients, this is primarily a counseling point: if your partner is pregnant or planning pregnancy, discuss finasteride discontinuation with your prescriber. The drug's half-life is five to six hours, and DHT levels return to baseline within approximately 14 days of stopping.